This facility, which will be managed by The Immune Tolerance Institute (ITI) and located initially at Beckman Coulter’s Cellular Analysis Business Group in Miami, will integrate state-of-the-art genomic, cellular, proteomic and bioinformatic technology platforms. The center will work with academic and corporate partners to discover and develop novel, high-value biomarkers that more effectively guide new drug development, including companion diagnostics that match patients with therapies that will provide them the greatest benefit.
Louis Matis, President and CEO of ITI, said: “The establishment of this center is the first step in bringing to fruition our mission to transform the drug discovery process to one that identifies promising therapies in their early phases of development, and that produces drug candidates that are safer, more highly targeted and effective in treating immune system-related diseases.”